Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds

被引:321
作者
Obach, R. Scott [2 ]
Lombardo, Franco [1 ]
Waters, Nigel J.
机构
[1] Novartis Inst Biomed Res, Metab & Pharmacokinet Grp, Cambridge, MA 02139 USA
[2] Groton Labs, Pfizer Global Res & Dev, Pharmacokinet Dynam & Metab, Groton, CT USA
关键词
D O I
10.1124/dmd.108.020479
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We present herein a compilation and trend analysis of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data. This data set provides the drug metabolism scientist with a robust and accurate resource suitable for a number of applications, including in silico modeling, in vitro-in vivo scaling, and physiologically based pharmacokinetic approaches. Clearance, volume of distribution at steady state, mean residence time, and terminal phase half-life were obtained or derived from original references exclusively from studies utilizing i.v. administration. Plasma protein binding data were collected from other sources to supplement these pharmacokinetic data. These parameters were analyzed concurrently with a range of simple physicochemical descriptors, and resultant trends and patterns within the data are presented. Our findings with this much expanded data set were consistent with earlier described notions of trends between physicochemical properties and pharmacokinetic behavior. These observations and analyses, along with the large database of human pharmacokinetic data, should enable future efforts aimed toward developing quantitative structure-pharmacokinetic relationships and improving our understanding of the relationship between fundamental chemical characteristics and drug disposition.
引用
收藏
页码:1385 / 1405
页数:21
相关论文
共 33 条
[1]   Allometric scaling of pharmacokinetic parameters in drug discovery:: Can human CL, VSS and t1/2 be predicted from in-vivo rat data? [J].
Caldwell, GW ;
Masucci, JA ;
Yan, ZY ;
Hageman, W .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2004, 29 (02) :133-143
[2]   MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist [J].
Cruciani, G ;
Carosati, E ;
De Boeck, B ;
Ethirajulu, K ;
Mackie, C ;
Howe, T ;
Vianello, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6970-6979
[3]   Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs [J].
Daniel, WA ;
Wojcikowski, J .
PHARMACOLOGY & TOXICOLOGY, 1997, 80 (02) :62-68
[4]   Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics [J].
Evans, Christopher A. ;
Jolivette, Larry J. ;
Nagilla, Rakesh ;
Ward, Keith W. .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) :1255-1265
[5]   Prediction of human pharmacokinetics - evaluation of methods for prediction of volume of distribution [J].
Fagerholm, Urban .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (09) :1181-1190
[6]   QSPR models for the prediction of apparent volume of distribution [J].
Ghafourian, Taravat ;
Barzegar-Jalali, Mohammad ;
Dastmalchi, Siavoush ;
Khavari-Khorasani, Tina ;
Hakimiha, Nasim ;
Nokhodchi, Ali .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 319 (1-2) :82-97
[7]   Structural basis of the drug-binding specificity of human serum albumin [J].
Ghuman, J ;
Zunszain, PA ;
Petitpas, I ;
Bhattacharya, AA ;
Otagiri, M ;
Curry, S .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 353 (01) :38-52
[8]   Plasma protein binding affinity and its relationship to molecular structure: An in-silico analysis [J].
Gleeson, M. Paul .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (01) :101-112
[9]   In silico human and rat Vss quantitative structure-activity relationship models [J].
Gleeson, MP ;
Waters, NJ ;
Paine, SW ;
Davis, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (06) :1953-1963
[10]  
Goodman LS, 2006, PHARM BASIS THERAPEU